US45166A1025
© PR Newswire
10.12.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
News Preview
Phase 1 dose escalation trial of monotherapy IDE574 expected to begin in 1Q 2026Targeting to present preclinical data detailing pharmacologic profile and evidence of anti-tumor activity in solid tumor models at a medical conference in 1H 2026SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leadi...
Themefolio
Profiler
Peergroup
© PR Newswire
01.12.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
News Preview
B7H3 and PTK7 is co-expressed in multiple solid tumor types, including lung, colorectal, and head and neck cancers, at approximately 30%, 46%, and 27%, respectivelyDeep and durable regressions observed with IDE034 monotherapy in multiple preclinical in-vivo models with B7H3 and PTK7 co-expressionEnhanced durability with IDE034 and IDE161 PARG inhi...
Themefolio
Profiler
Peergroup
© PR Newswire
28.11.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Nov. 28, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on November 26, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to p...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
24.11.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events
News Preview
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
04.11.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Phase 2/3 trial (OptimUM-02) of the darovasertib/crizotinib combination in 1L HLA*A2-negative metastatic uveal melanoma (mUM) to report median PFS data by year-end 2025 to 1Q 2026; on track to complete enrollment by year-end
21.1 month median OS and 7.0 month median PFS reported from single-arm...
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on October 30, 2025, the Compensation Committee of IDEAYA's Board of Directors grante...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025
News Preview
83% (78/94) of patients demonstrated ocular tumor shrinkage, with 54% (51/94) achieving ≥20% tumor shrinkage
57% (24/42) eye preservation rate in enucleation (EN) recommended patients, which increased to 95% (19/20) in patients achieving ≥20% ocular tumor shrinkage
70% (26/37)...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
News Preview
Combination demonstrated median overall survival (OS) of 21.1 months, compared to reported historical mOS of approximately 12 months in published meta-analysis of metastatic uveal melanoma in the first-line setting
Median progression free survival (PFS) of 7.0 months
Confirmed...
Themefolio
Profiler
Peergroup
© PR Newswire
26.09.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on September 25, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options t...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma
News Preview
Treatment with darovasertib resulted in robust ocular tumor shrinkage, lower simulated radiation doses to the eye and meaningful visual gains and reduced long-term risk of blindness for patients in the neoadjuvant setting of primary uveal melanomaManageable safety profile with mostly Grade 1 and 2 treatment-related adverse eventsPhase 3 registrat...
Themefolio
Profiler
Peergroup
© PR Newswire
07.09.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer
News Preview
80.0% (8/10) ORR and 70.0% (7/10) confirmed ORR in 2L SCLC; a 73.7% (14/19) ORR and 57.9% (11/19) confirmed ORR (1 pending confirmation) were observed across all lines of SCLC at the 2.4 mg/kg expansion dose of IDE84977.1% (27/35) ORR and 60.0% (21/35) confirmed ORR (4 pending confirmation) in 2L SCLC; a 73.2% (52/71) ORR and 47.9% (34/71) confir...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
IDYA
LISTED
NASDAQ
Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
News Preview
Servier and IDEAYA Biosciences enter into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the USDarovasertib is a small molecule developed for patients with uveal melanoma, a rare type of eye cancer with high unmet medical needIDEAYA will receive an upfront payment of $210 million and up to $320 million...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
29.08.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on August 28, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to pu...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events
News Preview
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events....
Themefolio
Profiler
Peergroup
© PR Newswire
18.08.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025
News Preview
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics for its in-person R&D Day in conjunction with the company's 10-Year Anniversary on September 8, 2025 in New York...
Themefolio
Profiler
Peergroup
© PR Newswire
01.08.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Aug. 1, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on July 31, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purch...
Themefolio
Profiler
Peergroup
© PR Newswire
24.07.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma
News Preview
The presentation will include data from over 90 patients in both the plaque brachytherapy and enucleation-eligible cohortsDarovasertib has received U.S. FDA Breakthrough Therapy Designation for use in neoadjuvant uveal melanoma for subjects requiring enucleationInitiated a multi-site, global randomized Phase 3 neoadjuvant registrational trial in...
Themefolio
Profiler
Peergroup
© PR Newswire
22.07.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC
News Preview
Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1 trialData will include patients from the dose escalation and at multiple expansion dosesU.S. Phase 1 trial of IDE849 in SCLC patients initiated in 3Q 2025JIANGSU, China and SOUTH SAN FRANCISC...
Themefolio
Profiler
Peergroup
© PR Newswire
21.07.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event
News Preview
SOUTH SAN FRANCISCO, Calif., July 21, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations event....
Themefolio
Profiler
Peergroup
© PR Newswire
27.06.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., June 27, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on June 26, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purc...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events
News Preview
SOUTH SAN FRANCISCO, Calif., June 2, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events....
Themefolio
Profiler
Peergroup
© PR Newswire
30.05.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., May 30, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on May 29, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purcha...
Themefolio
Profiler
Peergroup
© PR Newswire
06.05.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
News Preview
~$1.05 billion of cash, cash equivalents and marketable securities as of March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities ongoingOver 300 patients enrolled in darovasertib and crizotinib registrational 1L HLA-A2-negative MUM trial; targeting median PFS results by YE 2025 to enable potential accelerate...
Themefolio
Profiler
Peergroup
© PR Newswire
06.05.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors
News Preview
Targeting to evaluate IDE849 (SHR-4849) in SCLC, NETs, and other DLL3-upregulated solid tumors, and in combination with IDE161/PARG to potentially enhance durabilityTargeting to present clinical data of over 40 SCLC patients, including the dose escalation and expansion, from partner Hengrui at medical conference in Q3 2025SOUTH SAN FRANCISCO, Cal...
Themefolio
Profiler
Peergroup
© PR Newswire
28.04.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events
News Preview
SOUTH SAN FRANCISCO, Calif., April 28, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events....
Themefolio
Profiler
Peergroup
© PR Newswire
25.04.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., April 25, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 24, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to pu...
Themefolio
Profiler
Peergroup
© PR Newswire
14.04.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma
News Preview
Targeting to initiate Phase 3 randomized registrational trial for darovasertib in the neoadjuvant setting in primary UM in H1 2025Clinical endpoints supportive of full approval based on FDA Type D Meeting: Eye preservation rate as the primary endpoint for enucleation patients. Proportion of patients with best corrected visual acuity 15-letter los...
Themefolio
Profiler
Peergroup
© PR Newswire
10.04.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer
News Preview
Initiated Phase 1/2 study expansion for IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy®, Gilead's Trop-2 directed ADC, in MTAP-deletion urothelial cancer based on preliminary safety and clinical efficacy dataMTAP-deletion prevalence in urothelial cancer is estimated to be approximately 26%SOUTH SAN FRANCISCO, Calif., April 10, 202...
Themefolio
Profiler
Peergroup
© PR Newswire
01.04.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events
News Preview
SOUTH SAN FRANCISCO, Calif., April 1, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events....
Themefolio
Profiler
Peergroup
© PR Newswire
31.03.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma
News Preview
Designation enables expedited development and priority regulatory reviewBTD application was supported by updated clinical data from Ph2 neoadjuvant UM trial that we are targeting to present at medical conferences in mid-2025 and H2 2025Targeting to initiate a Ph3 registrational study in neoadjuvant UM in H1 2025Neoadjuvant UM has a projected annu...
Themefolio
Profiler
Peergroup
© PR Newswire
28.03.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., March 28, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on March 27, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to pu...
Themefolio
Profiler
Peergroup
© PR Newswire
26.03.2025
IDYA
LISTED
NASDAQ
IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor
News Preview
4 IDEAYA/GSK presentations of IDE275 (GSK959) and 4 additional presentations across IDE397/MAT2A, IDE161/PARG, PRMT5, and KAT6/7 programs at AACR 2025IDE275 (GSK959) has demonstrated a potential best-in-class preclinical profile in the MSI-H setting, with a unique binding mode from previously reported WRN inhibitorsPhase 1 dose escalation trial o...
Themefolio
Profiler
Peergroup
© PR Newswire
03.03.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets
News Preview
SOUTH SAN FRANCISCO, Calif., March 3, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced a research collaboration with ATTMOS as part of its efforts to build a physics-based computational small molecule discovery p...
Themefolio
Profiler
Peergroup
© PR Newswire
10.02.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer
News Preview
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Joshua Bleharski, Ph.D. as Chief Financial Officer. Dr. Bleharski joins IDEAYA from J.P. Morgan, where he...
Themefolio
Profiler
Peergroup
© PR Newswire
31.01.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on January 30, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to p...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events
News Preview
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events....
Themefolio
Profiler
Peergroup
© PR Newswire
12.01.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance
News Preview
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 43rd Annual J.P. Morgan Healthcare Conference and provided 2025 corporate guidance and program updates....
Themefolio
Profiler
Peergroup
© PR Newswire
29.12.2024
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
News Preview
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)DLL3 highly expressed in Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NETs), respectively 85% and 20-40%Rational combination opportunities with IDEAYA's DNA Damage Repair (DDR) clinical pipeline, includi...
Themefolio
Profiler
Peergroup
© PR Newswire
27.12.2024
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Dec. 27, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on December 26, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to...
Themefolio
Profiler
Peergroup
© PR Newswire
16.12.2024
IDYA
LISTED
NASDAQ
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
News Preview
Nominated development candidate IDE251, a potential first-in-class KAT6/7 inhibitorIDE251 is targeted to be evaluated in breast and NSCLC with 8p11 amplification, and in the setting of lineage addiction. 8p11 amplification prevalence is projected to be ~15% in breast cancer and ~17.5% in squamous NSCLCDemonstrated robust and durable monotherapy a...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2024
IDYA
LISTED
NASDAQ
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024
News Preview
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics for its virtual Investor R&D Day. The webcast event will be hosted by IDEAYA on Monday, December 16, 2024 at 8:00...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2024
IDYA
LISTED
NASDAQ
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
News Preview
First patient dosed with combination of IDE161, IDEAYA's investigational, potential first-in-class PARG inhibitor, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapyThe IDEAYA-sponsored Phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of IDE161 in combination wi...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2024
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor
News Preview
IDE892 is a potent and selective MTA-cooperative PRMT5 inhibitor with favorable ADME properties; demonstrating robust MTAP deletion-specific pathway suppression and highly durable antitumor activity in combination with IDE397IND-enabling studies ongoing and targeting IND-filing for IDE892 in mid-2025SOUTH SAN FRANCISCO, Calif., Dec. 9, 2024 /PRNe...
Themefolio
Profiler
Peergroup
© PR Newswire
02.12.2024
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events
News Preview
SOUTH SAN FRANCISCO, Calif., Dec. 2, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations events....
Themefolio
Profiler
Peergroup
© PR Newswire
29.11.2024
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Nov. 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on November 27, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to...
Themefolio
Profiler
Peergroup
© PR Newswire
18.11.2024
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
News Preview
Brings over 20-year global commercialization experience in oncology with leading biopharmaceutical companies Gilead Sciences and Bristol Myers Squibb, including leadership of multiple commercial launches for products including Trodelvy® and Opdivo®SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2024
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
News Preview
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the Jefferies London Healthcare Conference and its plans to host an Investor R&D Day in December 2024....
Themefolio
Profiler
Peergroup
© PR Newswire
11.11.2024
IDYA
LISTED
NASDAQ
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen
News Preview
Nominated IDE034 (BCG034) as a development candidate, a potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC)Option exercised for an exclusive worldwide license for IDE034 from BiocytogenTargeting an IND-filing for IDE034 in 2025 to enable first-in-human clinical evaluation of B7H3/PTK7 topo-I-payload BsADC...
Themefolio
Profiler
Peergroup
© BusinessWire
11.11.2024
IDYA
LISTED
NASDAQ
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
News Preview
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, has exercised the option...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2024
IDYA
LISTED
NASDAQ
IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update
News Preview
Enrollment in darovasertib + crizotinib 1L HLA-A2(-) MUM potential Ph2/3 registration-enabling trial is ahead of schedule and has exceeded 150 patientsSuccessful FDA Type C meeting and targeting initiation of Ph3 registration-enabling trial for darovasertib in neoadjuvant UM in H1 2025; Phase 2 neoadjuvant update with ~49% with >30% ocular tum...
Themefolio
Profiler
Peergroup
© PR Newswire
01.11.2024
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Nov. 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on October 31, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to pu...
Themefolio
Profiler
Peergroup
© PR Newswire
28.10.2024
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors
News Preview
IDE275 (GSK959) development is progressing into First-in-Human Phase 1 clinical trial(s) for the treatment of MSI-High solid tumors, representing IDEAYA's 5th potential first-in-class clinical programMSI-High prevalence in endometrial, colorectal, and gastric cancers is ~31%, 20%, and 19%, respectively, highlighting the market potential of IDE275...
Themefolio
Profiler
Peergroup
© PR Newswire
04.10.2024
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium
News Preview
SOUTH SAN FRANCISCO, Calif., Oct. 4, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a late-breaking oral presentation of the Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor in methylthioad...
Themefolio
Profiler
Peergroup
© PR Newswire
27.09.2024
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on September 26, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options t...
Themefolio
Profiler
Peergroup
© PR Newswire
23.09.2024
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma
News Preview
Phase 2 company-sponsored and IST neoadjuvant uveal melanoma (UM) clinical data update in 49 evaluable patients, demonstrates ~49% of patients with >30% tumor shrinkage by product of diameters, and ~61% eye preservation rate for enucleation patientsTargeting to initiate Phase 3 randomized registrational trial in neoadjuvant UM following finali...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2024
IDYA
LISTED
NASDAQ
IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024
News Preview
SOUTH SAN FRANCISCO, Calif., Sept. 22, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that the company plans to issue a pre-market press release and conduct an investor webcast on Monday, September 23, 2024,...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2024
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel
News Preview
Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of target...
Themefolio
Profiler
Peergroup
© PR Newswire
30.08.2024
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on August 29, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to pu...
Themefolio
Profiler
Peergroup
© PR Newswire
26.08.2024
IDYA
LISTED
NASDAQ
IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference....
Themefolio
Profiler
Peergroup
© PR Newswire
23.08.2024
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Aug. 23, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on August 19, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to pu...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
